Mind Medicine (mindmed) INC 8-K filings

MindMed reported positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), along with a strong cash position of $252.3 million as of March 31, 2024.

MindMed will delist its common shares from Cboe Canada on April 10, 2024, to consolidate trading on Nasdaq.

MindMed has successfully priced a $175 million capital raise through a public share offering and a concurrent private placement, aimed at funding research and development and general corporate purposes.

MindMed's MM120 demonstrated significant and durable improvement in Generalized Anxiety Disorder symptoms in a Phase 2b trial, with a 7.7-point improvement over placebo at 12 weeks.

MindMed's MM120 program for generalized anxiety disorder (GAD) has been granted breakthrough therapy designation by the FDA, and a Phase 2b trial demonstrated significant and durable efficacy through 12 weeks.

MindMed reported positive topline Phase 2b data for MM120 in Generalized Anxiety Disorder (GAD) and provided a financial update for the year ended December 31, 2023.